150 results on '"Undre, Nasrullah"'
Search Results
2. Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study
3. Validation of a Capillary Dry Blood Sample MITRA-Based Assay for the Quantitative Determination of Systemic Tacrolimus Concentrations in Transplant Recipients
4. Quantitation of Tacrolimus in Human Whole Blood Samples Using the MITRA Microsampling Device
5. A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation
6. Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction
7. Co-infections: testing macrolides for added benefit in patients with COVID-19
8. Increase in tacrolimus trough levels after steroid withdrawal
9. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label study
10. Pharmacokinetics for once-daily versus twice-daily tacrolimus formulations in de novo liver transplantation: A randomized, open-label trial
11. Intermittent micafungin for prophylaxis in a rat model of chronic Candida albicans gut colonization
12. Long-Term Kidney Transplant Outcomes: Role of Prolonged-Release Tacrolimus
13. Long‐term, prolonged‐release tacrolimus‐based immunosuppression in de novo kidney transplant recipients: 5‐year prospective follow‐up of the ADHERE study patients
14. Cover
15. Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus
16. Efficacy and safety of prolonged‐release tacrolimus in stable pediatric allograft recipients converted from immediate‐release tacrolimus – a Phase 2, open‐label, single‐arm, one‐way crossover study
17. Poster Board #-Session: P100-I PK Modelling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving Once-Daily Tacrolimus (ADVAGRAF).: Abstract# 757
18. The pharmacokinetics of tacrolimus after first and repeated dosing with 0.03% ointment in infants with atopic dermatitis
19. Pharmacokinetics of 0.1% Tacrolimus Ointment After First and Repeated Application to Adults with Moderate to Severe Atopic Dermatitis
20. A Multicenter Study of the Pharmacokinetics of Tacrolimus Ointment after First and Repeated Application to Children with Atopic Dermatitis
21. Validation of a Capillary Dry Blood Sample MITRA-Based Assay for the Quantitative Determination of Systemic Tacrolimus Concentrations in Transplant Recipients.
22. Quantitation of Tacrolimus inHuman Whole Blood Samples Using the MITRA Microsampling Device.
23. Pharmacokinetics of tacrolimus-based combination therapies
24. The Effect of Donor Age and Recipient Characteristics on Renal Outcomes in Patients Receiving Prolonged-Release Tacrolimus After Liver Transplantation: Post-Hoc Analyses of the DIAMOND Study
25. Pharmacokinetic Profile of Prolonged-Release Tacrolimus When Administered via Nasogastric Tube in De Novo Liver Transplantation: A Sub-Study of the DIAMOND Trial
26. Comparative pharmacokinetics of tacrolimus in stable pediatric allograft recipients converted from immediate‐release tacrolimus to prolonged‐release tacrolimus formulation
27. Comparative pharmacokinetics of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus
28. Long‐term, prolonged‐release tacrolimus‐based immunosuppression in de novo kidney transplant recipients: 5‐year prospective follow‐up of the ADHERE study patients.
29. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies
30. Pharmacokinetics of prolonged-release tacrolimus versus immediate-release tacrolimus in de novo liver transplantation: A randomized phase III substudy
31. Relative bioavailability of single doses of prolonged-release tacrolimus administered as a suspension, orally or via a nasogastric tube, compared with intact capsules: a phase 1 study in healthy participants
32. Pharmacokinetics of tacrolimus granules in pediatric de novo liver, kidney, and heart transplantation: The OPTION study.
33. Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients
34. Effect of Breakfast on the Exposure of the Once-Daily Tacrolimus Formulation in Stable Kidney Transplant Recipients.
35. Pharmacokinetics of micafungin in subjects with severe hepatic dysfunction
36. Lower Variability in 24-Hour Exposure During Once-Daily Compared to Twice-Daily Tacrolimus Formulation in Kidney Transplantation
37. Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects
38. Optimizing Micafungin Dosing in Children
39. Tacrolimus Pharmacokinetics of Once- Versus Twice-Daily Formulations in De Novo Kidney Transplantation
40. Pharmacokinetics in Stable Kidney Transplant Recipients After Conversion From Twice-Daily to Once-daily Tacrolimus Formulations
41. Pharmacokinetics of Micafungin in Adult Patients with Invasive Candidiasis and Candidemia
42. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants:* a two-year open-label study
43. Pharmacokinetics in stable heart transplant recipients after conversion from twice-daily to once-daily tacrolimus formulations
44. Pharmacokinetic Modeling and Development of Bayesian Estimators in Kidney Transplant Patients Receiving the Tacrolimus Once-Daily Formulation
45. Increase in tacrolimus trough levels after steroid withdrawal
46. A late episode of post-transplant diabetes mellitus during active hepatitis C infection in a renal allograft recipient using tacrolimus
47. Pharmacokinetics of Micafungin in Pediatric Patients With Invasive Candidiasis and Candidemia.
48. Renal Function Outcomes with Prolonged-Release Tacrolimus According to Donor Age after De Novo Liver Transplantation: A Post Hoc Analysis from the DIAMOND Randomized, Controlled Trial
49. Nabumetone pharmacokinetics in patients with varying degrees of renal impairment
50. γ-Cyclodextrin hydrogel for the sustained release of josamycin for potential ocular application.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.